Financial Performance - Celcuity reported a net loss of approximately $111.8 million for the year ended December 31, 2024, compared to a net loss of $63.8 million for 2023[314]. - The net loss for the year ended December 31, 2024, was $111.8 million, a 75% increase from the previous year[323]. - Net cash used in operating activities was approximately $83.5 million for the year ended December 31, 2024, compared to $53.8 million in 2023[345][346]. - Net cash used in investing activities for 2024 was approximately $63.1 million, significantly higher than $5.0 million in 2023[347][348]. - Net cash provided by financing activities for 2024 was approximately $138.4 million, up from $64.9 million in 2023[349][350]. - The company raised approximately $369.0 million in net proceeds through equity securities and convertible notes from inception through December 31, 2024[330]. - As of December 31, 2024, Celcuity had cash and cash equivalents of approximately $235.1 million and an accumulated deficit of approximately $271.9 million[314]. - As of December 31, 2024, the company had cash and cash equivalents of approximately $22.5 million and short-term investments of $212.6 million[330]. - The Company believes its current cash and available borrowings will be sufficient to finance clinical development activities through 2026[342]. - The Company may seek additional capital to finance future expenditures and operations, which could result in dilution to existing shareholders[343]. Research and Development - Gedatolisib has been administered to 492 patients across eight clinical trials, with 129 patients receiving it as a single agent[299]. - In the Phase 1b clinical trial, the overall response rate (ORR) for treatment-naïve patients was 85%, while the ORR for patients who received prior hormonal therapy ranged from 36% to 77%[302]. - The median progression-free survival (PFS) for treatment-naïve patients receiving gedatolisib combined with palbociclib plus letrozole was 48.6 months[303]. - The VIKTORIA-1 Phase 3 clinical trial is fully enrolled for the PIK3CA wild-type cohort, with topline data expected in Q2 2025[311]. - The VIKTORIA-2 Phase 3 trial is set to enroll its first patient in Q2 2025, evaluating gedatolisib in combination with fulvestrant and a CDK4/6 inhibitor[312]. - The FDA approved the clinical development of gedatolisib in combination with Nubeqa® for metastatic castration-resistant prostate cancer in mid-2023[307]. - The Phase 1b/2 study CELC-G-201 is currently enrolling patients with mCRPC, with initial data expected by the end of Q2 2025[309]. - Gedatolisib's unique mechanism of action targets all Class I isoforms of PI3K and both mTOR complexes, potentially overcoming limitations of existing therapies[294]. - The Company expects to incur increased research and development expenses as it continues to develop gedatolisib and manage multiple clinical trials[341]. - The company plans to increase research and development expenses to support ongoing clinical trials, including VIKTORIA-1 and VIKTORIA-2[325]. Expenses - Research and development expenses for the year ended December 31, 2024, were approximately $104.2 million, an increase of 72% compared to 2023[324]. - General and administrative expenses for the year ended December 31, 2024, totaled $9.1 million, reflecting a 61% increase from 2023[326]. - Interest expense for the year ended December 31, 2024, was $10.3 million, up 93% compared to 2023, primarily due to increased debt[328]. - Interest income for the year ended December 31, 2024, was $11.8 million, representing a 51% increase compared to 2023[329]. - The Company anticipates future increases in general and administrative expenses due to potential commercialization of gedatolisib and expanding infrastructure[327]. - The Company anticipates increased sales and marketing expenses as it commercializes gedatolisib[341]. Debt and Financing - The company entered into an Amended and Restated Loan and Security Agreement on May 30, 2024, with a total principal amount of up to $180 million[335]. - The Company recognized a Final Fee of $4.5 million as additional debt principal on May 30, 2024[338]. - The Company issued 103,876 warrants with an exercise price of $14.84 per share, with a relative fair value of approximately $1.2 million[340].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 29, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 333-233233 BT BRANDS, INC. (Exact name of registrant as specified in its charter) Wyoming 90-1495764 (State or other jurisdiction of incorporation or organization) 10701 Wayzata Blvd S ...

Exhibit 99.1 INTERACTIVE STRENGTH INC. Interactive Strength Inc. (Nasdaq: TRNR) Reports Fourth Quarter & Year-End 2024 Results Company Delivers Quarterly Revenue of $2.4 Million as Projected or $5.4 Million for full-year 2024 Quarterly Net Loss and Earnings per Diluted Share of $5.8 Million and $7.26 Quarterly Adjusted EBITDA Loss of $1.9 Million Reflects 42% Improvement YOY and 19% Sequentially Stockholders' Equity Was $7.1 Million at Year End Pending Acquisitions Remain on Track; TRNR Expects More than $5 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37997 SACHEM CAPITAL CORP. (Exact name of registrant as specified in its charter) New York 81-3467779 State or othe ...

Exhibit 99.1 Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights SAN DIEGO, March 31, 2025 — (Business Wire) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2024 operating and financial results and reviewed recent business highlights. "Calidi continues to make great progress on all thre ...

Financial Performance and Capital Raising - In Q4 2024, Calidi Biotherapeutics raised $9.5 million in gross proceeds from two public offerings, $2.0 million from warrant exercises, and $3.1 million from its at-the-market program[6] - A subsequent public offering in January 2025 raised an additional $4.25 million in gross proceeds[6] - The total capital raised has strengthened the company's cash position, allowing it to meet capital requirements without reliance on the Standby Equity Purchase Agreement (SEPA)[6] - The SEPA, which allowed the company to issue and sell up to $25.0 million of its common stock, was terminated effective January 23, 2025, with no outstanding borrowings or fees due[4][5] Financial Reporting and Estimates - The preliminary financial information provided is subject to further internal review and may differ from final results due to ongoing closing procedures[8][10] - Management's estimates are based on preliminary information and may change as actual results are compiled[9][10] Forward-Looking Statements and Risks - Forward-looking statements regarding future financial performance are subject to risks and uncertainties that could cause actual results to differ materially[11] - The company operates in a competitive environment, and new risks may emerge that could impact forward-looking statements[11] - The company has no obligation to update forward-looking statements unless required by law[12] Press Release and Communication - The press release regarding the bolstered cash balance and termination of the SEPA was issued on January 28, 2025[13]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41357 Yotta Acquisition Corporation (Exact name of registrant as specified in its charter) | Delaware | 85-3374167 | | --- | --- | | (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41357 Yotta Acquisition Corporation (Exact name of registrant as specified in its charter) | Delaware | 85-3374167 | | --- | --- | | (State or other ...

Financial Position - As of December 31, 2024, LGL Group had cash and cash equivalents and marketable securities with a fair market value of approximately $41,602, of which $24,609 was held within the Merchant Investment business[16][34]. - The company recorded $1.9 million of non-controlling interests in LGL Systems on its consolidated balance sheets as of June 2023[59]. - The company had investments in cash and cash equivalents and marketable securities with a fair market value of $41,602 as of December 31, 2024[81]. - Cash provided by operating activities increased by $489, or 127.0%, from $385 in 2023 to $874 in 2024, reflecting improved operational efficiency[210]. - Cash and cash equivalents at the end of 2024 were $41,585, an increase of $874 from $40,711 at the end of 2023[209]. - Working capital increased by $646, or 1.6%, from $41,092 in 2023 to $41,738 in 2024, with a current ratio of 47.2 in 2024 compared to 87.7 in 2023[211]. - The company believes existing cash and cash equivalents, marketable securities, and cash generated from operations will provide sufficient liquidity for ongoing working capital and capital expenditure requirements for the next 12 months[213]. Business Strategy and Operations - LGL Group's business strategy focuses on growth through expanding new and existing operations across diversified industries, having acquired 32 businesses since 1985[14][16]. - The Company aims to maximize shareholder value by developing businesses and positioning them as independent entities[18]. - The Merchant Investment segment utilizes various structures to build shareholder value, including special purpose vehicles and fee-generating activities[25][33]. - LGL Group's strategy includes identifying and acquiring undervalued assets and businesses, often through the purchase of securities[33]. - The company intends to explore acquisitions to enhance or expand its business, but faces risks related to integration and management attention[123]. - The company is currently dependent on a single line of manufacturing business following the separation of MtronPTI on October 7, 2022, which poses risks if demand declines[112]. Revenue and Sales Performance - In 2024, total sales reached $2,226,000, with the top four customers accounting for 43.0% of revenue[44]. - International revenues increased to $962,000, representing 43.2% of total sales, up from 39.1% in 2023[49]. - The order backlog as of December 31, 2024, was $336,000, compared to $143,000 in 2023, indicating growth in future sales potential[51]. - Total revenues increased by $614, or 16.7%, from $3,678 in 2023 to $4,292 in 2024[190]. - Net sales rose by $498, or 28.8%, from $1,728 in 2023 to $2,226 in 2024, primarily due to additional contracts won within the Electronic Instruments segment[195]. - The two largest customers accounted for 13.9% and 11.7% of net sales in 2024, down from 23.1% and 13.7% in 2023, indicating a shift in customer concentration risk[121]. Investment and Market Risks - The company may face substantial negative impacts on sales and operating results if there is a loss or decrease in sales among one of its top customers[1]. - The company may encounter significant risks related to its Merchant Investment business, including potential losses from investments in special purpose vehicles (SPVs)[82]. - The Merchant Investment business may leverage its capital to achieve higher returns, but this also increases the risk of significant losses[95]. - Investments in non-U.S. securities expose the Merchant Investment business to currency exchange risks and other potential risks not typically associated with U.S. investments[105]. - Credit risk may arise from defaults by large institutions, potentially causing systemic risks that adversely affect financial intermediaries[106]. - The insolvency of prime brokers or custodian banks may result in the loss of a substantial portion of the Merchant Investment business's assets[106]. Financial Results and Expenses - The company reported net income of approximately $432 million for the year ended December 31, 2024, compared to $269 million in 2023, reflecting higher net sales and net investment income[116]. - Total expenses rose by $561, or 18.5%, from $3,032 in 2023 to $3,593 in 2024[192]. - Manufacturing cost of sales increased by $251, or 31.5%, from $796 in 2023 to $1,047 in 2024, primarily due to several contracts with higher cost products[196]. - Engineering, selling, and administrative expenses increased by $310, or 13.9%, from $2,236 in 2023 to $2,546 in 2024, attributed to higher salaries and benefits[196]. - Gross margin decreased by 90 basis points from 53.9% in 2023 to 53.0% in 2024, primarily due to lower margin contracts[192]. Regulatory and Compliance Risks - The company is subject to procurement regulations as a supplier to U.S. Government defense contractors, which may impact its business[1]. - Increased regulation, such as the Dodd-Frank Act, may impose additional burdens and costs on the Merchant Investment business[99][100]. - Future changes in environmental regulations may increase costs and decrease profitability, affecting manufacturing processes and product designs[139]. Cybersecurity and IT Risks - Cybersecurity risk management is based on the NIST framework, with tailored controls to protect the confidentiality, integrity, and availability of systems[163]. - The company relies on IT systems, and any disruption or security breach could adversely affect business operations and financial performance[141]. - Cyber incidents could disrupt operations and compromise confidential information, negatively impacting financial results and business relationships[142]. Market Conditions and Economic Factors - The company’s financial results may be adversely affected by macroeconomic fluctuations, including inflation and changing interest rates[1]. - Inflation in the U.S. decreased from 6.5% at the end of 2023 to 2.9% at the end of 2024, but is expected to remain elevated in 2025, potentially impacting manufacturing costs[110]. - The U.S. Federal Reserve decreased the federal funds rate three times in 2024, resulting in a range from 4.25% to 4.50% as of December 31, 2024, with expectations for further decreases in 2025[111]. Stock and Shareholder Information - Approximately 37.3% of the voting power of the outstanding shares is controlled by officers, directors, and 10% or greater stockholders as of March 14, 2025, which may affect management decisions[146]. - The company is classified as a "smaller reporting company," with a market value of less than $250 million as of June 30, 2023, leading to simplified disclosure requirements[154]. - The common stock price fluctuated between $6.58 and $5.05 from January 1, 2024, to December 31, 2024, indicating significant volatility due to limited trading volume[143]. - The warrants to purchase shares of common stock have an adjusted exercise price of $4.75 and may not have any value if the market price does not exceed this amount by the expiration date of November 16, 2025[148].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41751 MDB CAPITAL HOLDINGS, LLC (Exact name of registrant as specified in its charter) Delaware 87-4366624 Securities registered pursuant to Section 12(b) of the Exchange Act: ...